The Latest Breaking News from Pfizer

The CDC has clarified and narrowed its recommendations for which older adults should get an RSV vaccine.

Moderna stock, which lost 27% of its value over two days, tumbled again Monday on a rare downgrade amid uncertainty for its vaccines.

Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations. Here's what investors should know.

Stocks fell Tuesday as the Fed meeting got underway. Microsoft fell ahead of earnings while Merck and Proctor & Gamble plunged after results.

The Dow Jones rose Tuesday, as the Federal Reserve's meeting kicks off. Microsoft earnings are up next on the stock market today.

Pfizer stock reversed higher Tuesday on a raised outlook for the year, driven by strong sales of heart and cancer drugs.

September S&P 500 E-Mini futures (ESU24) are trending up +0.17% this morning as market participants braced for the start of the Federal Reserve’s two-day policy meeting while also awaiting the latest reading on U.S. job openings as well as an earnings report from tech giant Microsoft.

Pfizer's stock shows signs of a potential rebound, buoyed by recent pipeline successes in hemophilia and obesity treatments, an attractive 5% dividend yield, and a rock-bottom valuation. This makes it an appealing dividend stock for value and income investors as the drug giant prepares to report earnings.

This week we have Apple, Advanced Micro Devices, Amazon, Pfizer, Coinbase, Meta Platforms, Intel, Exxon Mobil, Boeing, PayPal, Starbucks, McDonald’s and Chevron all set to report.